Columns - Pharmaceutical Executive

ADVERTISEMENT

Columns

Thought Leader: Scientific Expression

May 1, 2006

The investigators, other than the people at Merck, didn't know about [additional cardiovascular adverse events] for six months after the study was published. But one could argue we didn't have to know because it's not part of the predefined study.

Washington Report: Opportunity Knocks

May 1, 2006

The pharmaceutical companies in the Predictive Safety Consortium have agreed to cross-test each other's laboratory methods to determine which are most effective in detecting kidney, muscle, and liver toxicity.

Medical Education: Real-Time CME

May 1, 2006

Physicians' busy schedules can hinder their ability to keep up with the most timely data and treatment options. Getting a handle on information before—or even at the same time as—patients can be challenging.

From the Editor: Mixed Signals

May 1, 2006

Where is pharma going? Toward more science, and more political pressure on science. Toward greater patient responsibility—and more regulation-by-lawsuit. And forward. Let's not forget about forward.

Global Report: A Hope and a Payer

May 1, 2006

One health insurance company in The Netherlands is offering doctors a financial incentive to prescribe generic statins and proton pump inhibitors. Doctors and patients complained, but a court upheld the practice.

Legal: The Kickback Effect

May 1, 2006

Criminal penalties for violating the Foreign Corrupt Practices Act can be substantial. Businesses found guilty may be fined upwards of $2.5 million for each offense, or twice the amount gained as a result of the violation.

Pharm Exec Q&A: Japanese Wedding

May 1, 2006

Just how traditional marriages join a couple together from a common culture, Daiichi and Sankyo are merging based on a sense of having come from the same place, and facing the same future. But the art of integration lies in creating new ways of working that make the marriage bigger than the sum of its parts. Officiating the marriage is John Alexander, MD, head of pharma development for Daiichi Sankyo.

Leadership: It is Personal

May 1, 2006

Are large corporations, with massive bureaucracies and thousands of employees, capable of acknowledging employees' personal passions? They don't have a choice. Large numbers of talented people are leaving organizations because the corporate structure is not accommodating personal passion. The good news is that the great companies are starting to do something about it, which denotes a big change in business ideology. Bill Toppeta, president of MetLife International, recently told the Fordham Leadership Forum, at the Fordham Graduate School of Business, "What you need to know as the leader is what motivates your people, not what motivates you."

Back Page: Risk Assessment

May 1, 2006

Genomic researchers are developing tools to determine whether the right patients are taking statins.

ADVERTISEMENT

Click here